ASIA unversity:Item 310904400/16111
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 90587/105803 (86%)
造訪人次 : 16745770      線上人數 : 32
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    題名: A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
    作者: Xie, X;Hsu, J.L.;Choi, M-G;Xia, W;Yamaguchi, H;Chen, C-T.;Trinh, B.Q.;Lu, Z;Ueno, N.T;Wolf, J.K;Bast, R.C.Jr.;洪明奇;Hung, Mien-Chie
    貢獻者: 生物科技學系
    日期: 2009
    上傳時間: 2012-11-23 17:08:41 (UTC+8)
    摘要: Currently, an effective gene therapy strategy, which not only retains cancer-specific expression but also limits toxicity, has yet to be developed for ovarian cancer. Mounting reports over the years have shown that human telomerase activity is significantly elevated in cancer cells compared with normal cells. In this study, we evaluated the human telomerase reverse transcriptase (hTERT; T) promoter and showed that it can direct target gene expression preferentially in ovarian cancer cells. However, its promoter (T) activity is much lower than that of cytomegalovirus (CMV), a commonly used nonspecific promoter. To overcome this problem, we have integrated the T promoter into our recently developed VP16-Gal4-WPRE integrated systemic amplifier (VISA) system and dramatically enhanced transgene expression. In addition, to further develop this cancer-specific promoter gene expression system into an applicable therapeutic vector, we expressed E1A (an adenoviral type 5 transcription factor that possesses anticancer properties) through this novel VISA platform. We showed that the T-VISA system specifically targeted the expression of E1A to ovarian cancer cells at a level greater than or comparable with the commonly used CMV promoter, yet remained nearly silent in normal cells, thus making this a suitable gene therapy construct. By using this cancer-specific promoter that limits target gene expression in normal cells/tissues, potential toxicity induced by the CMV promoter would be prevented. More importantly, we showed significant antitumor activity with much less toxicity in animal models through i.v. delivery of T-VISA-E1A:liposomal nanoparticles, suggesting a promising role of T-VISA-E1A for ovarian cancer treatment under a gene therapy setting.
    關聯: Molecular Cancer;8(8):2375-82.
    顯示於類別:[生物科技學系] 期刊論文


    檔案 描述 大小格式瀏覽次數


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋